News

Under the terms of the transaction, Martek will pay consideration of $200m, subject to working capital adjustments, of which $120m will be paid from its current cash reserves

The agreement gives Ferrer inCode, a biotech subsidiary of Grupo Ferrer Internacional, the right to sell and market ADtect initially in Germany, Belgium, the Netherlands, Luxemburg, France, Italy,

The company said that the facility has been designed for the supply of late-phase clinical trial tablet and capsule products, and will be capable of handling batch sizes

As a result, the scientific/technical review procedure commenced on 21 January 2010. Xiaflex is a biologic for the treatment of dupuytren’s contracture. Based on the completion of the

The companies said that the agreement is expected to provide researchers in the Asian market access to quality modified nucleic acid products, to further advance research efforts in

Equa, marketed as Galvus in the EU, has been approved in Japan for the treatment of type 2 diabetes, as monotherapy or in combination with a sulfonylurea. As

OBI-1 is indicated for the treatment of patients with acquired hemophilia and hemophilia A, who have developed an inhibitory immune reaction to human forms of factor VIII. IB1001

Reportedly, ChemPoint will manage the complete order and fulfillment process for SolVin’s Ixan SGA-1 PVDC resin, from order placement to delivery to technical support. Diego Lancksweert, business manager

GAI-122 is being developed as IV administered formulation of an intracellular neuro-protectant that employs AlphaRx’s proprietary nano-emulsion formulation technology. More specifically, GAI-122 is being developed for the amelioration